Nanoform Finland (NANOFH) Q4 2025 earnings summary

Executive summary

• Launched breakthrough strategies for both small and large molecules, leveraging proprietary CESS® and BioLine technologies to enable a shift from IV to subcutaneous delivery in biologics, with a goal of three nanoformed medicines and >50% CAGR with EBIT margin >30% by 2030.

• Achieved significant milestones: new IP, industrial-scale readiness, GMP batches for key products, commercial deals in five countries, and expansion into Asia.

• Major US pharma partnership, new patent granted in the USA, and commercial cGMP manufacturing license for Europe.

• Revenue increased 28% year-over-year to EUR 3.5 million, driven by 53 customer projects and improved gross margin to 86% from 80%.

• Workforce reduced by 6% to 171 employees, with further cost-saving measures announced for 2026.

Financial highlights

• Record revenue and other operating income in 2025, with first-time income from associated companies and Q4 revenue up 79% year-over-year to EUR 1.3 million.

• EBITDA improved year-over-year, with loss narrowed to EUR -15.2 million from EUR -21.0 million, and operating loss at EUR -18.5 million.

• Cash position at year-end was EUR 24.0 million, providing a comfortable runway.

• Cost reductions and change negotiations expected to lower annual cash burn by EUR 5–6 million.

• Full-year gross profit rose to EUR 3.0 million, with total operating costs down 9% to EUR 22.6 million.

Outlook and guidance

• Targets for 2026 include cash burn below EUR 10 million, first marketing authorization application for a nanoformed medicine, and increased project signings.

• Mid-term goals for 2030: launch three nanoformed medicines, achieve >50% CAGR income growth (2026–30), and EBIT margin above 30%.

• Strategic planning underway for commercial launch of Nanoenzalutamide in Europe by 2028.

• Milestone payments from new and existing kernels could further improve cash flow.